Drug intelligence / Profile preview

C-AM-01

Development stage: Unknown
Lead developer: Curatis
Modality: Small Molecules
Administration: Oral

Overview

C-AM-01 is a repurposed formulation of picotamide, a small molecule dual thromboxane A2 (TXA2) synthase inhibitor and thromboxane A2 receptor (TP) antagonist. Developed by Curatis Group and its spin-off CapiThera, it is currently in Phase 2 clinical development for the prevention of severe migraine with aura (MwA). By targeting both the production and the receptor-mediated actions of thromboxane A2, C-AM-01 aims to address the vasoactive and pro-thrombotic mechanisms associated with the cortical spreading depression and vascular changes characteristic of migraine with aura. The drug addresses a significant unmet medical need in the severe segment of patients with aura.

Other names: picotamide

Targets

TYMP (Thymidine phosphorylase)TBXAS1 (Thromboxane A2 synthase)

Beyond the preview

Go deeper on C-AM-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-AM-01.

Explore the full profile